CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates U.S. FDA clears lung cancer IND for CVHNLC , a proprietary off-the-shelf candidate targeting squamous non-small cell lung ca

CureVac Announces Financial Results for the

First Quarter of 2025 and Provides Business Updates

T BINGEN, Germany / BOSTON, USA - May 20,

2025 - CureVac N.V. (Nasdaq: CVAC), a pioneering multinational biotech company developing a new class of transformative medicines

based on messenger RNA (mRNA), today announced financial results for the first quarter of 2025 and provided a business update.

"We entered 2025 with a strong momentum and robust balance sheet,

driven by progress across our oncology and infectious disease programs, as well as successful execution of our strategic realignment,"

said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. "With the FDA's clearance of the IND for our lung cancer

program and our glioblastoma study fully enrolled, we are steadily advancing an oncology pipeline that addresses high-unmet-need tumors.

At the same time, we believe the European Patent Office's recent rulings upholding two of our patents in amended form confirm the

strength of our mRNA intellectual property estate. Backed by 438 million in cash, we are well positioned to unlock multiple pipeline

catalysts later this year and continue to expand and execute on our next generation mRNA portfolio."

Selected Business Updates

CureVac is strengthening its oncology pipeline following two complementary

approaches: off-the-shelf precision immunotherapies targeting tumor antigens shared across different patient populations and/or tumor

types as well as fully personalized precision immunotherapies based on a patient's individual tumor genomic profile.

Prophylactic Vaccines

Protection of Intellectual Property Rights

Financial Update for the First Quarter of 2025

Cash and cash equivalents amounted to

438.3 million at the end of March 2025, decreasing from 481.7 million at the end of December 2024. In the first

three months of 2025, cash used in operations was mainly allocated to ongoing research and development (R&D) activities to advance

candidates in oncology precision immunotherapies and prophylactic vaccines and to further develop CureVac's mRNA technology.

As a result of the strategic restructuring initiated in July 2024, the cash outflow for the first quarter of 2025 decreased compared

to the first quarter of 2024. CureVac completed the intended workforce reduction as part of the strategic restructuring resulting in decreased

personnel expenses, while implementing further cost reductions and increasing cost discipline through the organization. The company reaffirms

its expected cash runway into 2028.

Revenues amounted to 0.9 million for the first

quarter of 2025, representing a decrease of 11.5 million from 12.4 million for the same period in 2024.

The year-on-year decrease was primarily driven by lower

revenues from GSK following the restructuring of the partnership in July 2024 from a Collaboration into a Licence Agreement as well

as lower sales to CRISPR Therapeutics.

For the three months ending March 31, 2025, total

revenues of 0.3 million and 0.6 million were recognized with GSK and CRISPR Therapeutics, respectively, compared to 8.9

million and 3.5 million in the prior year period.

Operating loss amounted to 54.7 million for the

first quarter of 2025, representing a decrease of 18.6 million from 73.3 million for the same period in 2024.

The decrease year-over-year is primary attributable

to the implemented cost reductions initiated with the strategic restructuring in July 2024:

Financial Result (Finance Income and Expenses)

Net financial result for the first quarter of 2025

amounted to 3.0 million, representing a decrease of 0.4 million from 3.4 million for the same period in 2024.

Pre-tax loss was 51.7 million for the first quarter

of 2025, compared to 69.9 million in the same period of 2024.

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company

founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of

developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined

key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork

for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics

and computational tools, to design and develop off-the-shelf and personalized precision immunotherapy candidates to treat cancer. It

also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins.

Headquartered in T bingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information

can be found at www.curevac.com.

CureVac Media and Investor Relations Contact

CureVac, T bingen, Germany

Forward-Looking Statements of CureVac

This press release contains statements that constitute "forward

looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements

that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned

subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium

SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that

reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates

and the company's strategies, financing plans, cash runway expectations, timing of various milestones, the impact of restructuring,

growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate,"

"intend," "believe," "estimate," "plan," "seek," "project," "expect,"

"may," "will," "would," "could," "potential," "intend," or "should,"

the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions

and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's

performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties

and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide

financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing,

expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products,

ability to manufacture any products, ability to implement our pipeline strategy, possible changes in current and proposed legislation,

regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects

of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, ability to implement, maintain

and improve effective internal controls, reliance on key personnel, reliance on intellectual property protection and the company's

and the company's collaborators' ability to obtain, maintain, defend and enforce such intellectual property, scope of intellectual

property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays

in litigation proceedings, different judicial outcomes and other important factors discussed under the caption "Risk Factors"

in the company's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC")

on April 11, 2025, as such factors may be updated form time to time in its other filings with the SEC. Such risks and uncertainties

may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks

are outside of the company's control and could cause its actual results to differ materially from those it thought would occur.

The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and

specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements

to reflect future events or developments, except as required by law.

For further information, please reference the company's reports

and documents filed with the SEC. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Cash and Condensed Consolidated Profit and Loss